Immunopathogenesis of psoriasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 70, Issue 1, 2004, Pages 10-12

  Joshi, Rajiv ^a,b  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b NONE   (India)

Author keywords

Immunology; Pathogenesis; Psoriasis

Indexed keywords

ALEFACEPT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANTIGEN SPECIFICITY; CELL FUNCTION; CELL INTERACTION; CYTOKINE RELEASE; EFFECTOR CELL; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; PATHOGENESIS; PHOTOTHERAPY; PSORIASIS; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 26944485738     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. Mehlis SL, Gordon KB. The immunulogy of psoriasis and biological immunotherapy. J Am Acad Dermatol 2003;49: (Suppl):S44-50.
2. Miller GT, Hochman PS, Meier W, Tizard R, Bixlor SA, Rosa MD, et al. Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-22.
3. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti CD 11 treatment for psoriasis increases circulating T cells and decreased plaque T cells, consistent with inhibition of cutaneous T cell trafficking. J Invest Dermatol 2000;115:333.
4. Peppel K, Crawford D, Beutler B. A tumour necrosis factor receptor IgG heavy chain chimeric protein as a covalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
5. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy & safety of Infliximab monotherapy for plaque type psoriasis. Lancet 2001;357:1842-7.